Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 9, Pages 3794-3805Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI99169
Keywords
-
Categories
Funding
- Intramural Research Program of the NIH, NCI, CCR
- Henry Wellcome Trust, United Kingdom [WT103973MA]
Ask authors/readers for more resources
Control of cellular metabolism is critical for efficient cell function, although little is known about the interplay between cell subset-specific metabolites in situ, especially in the tumor setting. Here, we determined how a macrophage-specific (M phi-specific) metabolite, itaconic acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors (B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation-mediated increase in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue-resident macrophages (pResM phi). Unbiased metabolomics identified itaconic acid, the product of immune-responsive gene 1-mediated (Irg1-mediated) catabolism of mitochondrial cis-aconitate, among the most highly upregulated metabolites in pResM phi of tumor-bearing mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in pResM phi and ROS-mediated MAPK activation in tumor cells. Our findings demonstrate that tumors profoundly alter pResM phi metabolism, leading to the production of itaconic acid, which potentiates tumor growth. Monocytes isolated from ovarian carcinoma patients' ascites fluid expressed significantly elevated levels of IRG1. Therefore, IRG1 in pResM phi represents a potential therapeutic target for peritoneal tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available